Preliminary Anticonvulsant and Toxicity Screening of Substituted Benzylidenehydrazinyl-N-(6-substituted benzo[d]thiazol-2-yl)propanamides

Table 5

Phase IV quantitative anticonvulsant evaluation of selected active compounds after oral administration.

Compound	TPE^a (h)	(mg/kg)	(mg/kg)	PI^d
5h	2	39.8 (33.1–44.5)^e	456.3 (419.2–502.2)	11.4
5p	2	48.5 (41.3–54.6)	689.1 (643.8–720.4)	14.2
PHY	2	9.16 (7.9–11.4)	87.6 (78.3–98.4)	9.56

Time of peak pharmacodynamic activity.
^bED₅₀ median effective dose eliciting anticonvulsant protection in 50% animals.
^cTD₅₀ median toxic dose eliciting minimal neurological toxicity in 50% animals.
^dPI (protective index) was determined by TD₅₀/ED₅₀.
^e95% confidence interval in parenthesis.